PALSONIFY logo
palsonify logo
PALSONIFY logo

Support and resources

Support every step of the way

David,

taking PALSONIFY

CrinetiCARE®

Support your patients can count on

Access and reimbursement support

CrinetiCARE offers personalized support to help your eligible patients throughout their treatment journey with PALSONIFY.

Icon of a magnifying glass

Benefits investigation

Icon of a stamp

Prior authorization support

Icon of a gavel

Appeals support

Get started
Patient Patricia: living with acromegaly.

Patricia,

living with acromegaly

Resource library

Find the materials you need to support informed care—from clinical insights to patient education. Download brochures, guides, and tools built to help you introduce, explain, and manage treatment with PALSONIFY.

Patient brochure

palsonify patient brochure.

An informational brochure for your patients with key facts about living with acromegaly, how PALSONIFY works, and what to expect when taking PALSONIFY.

iconDownload PDF

PATHFNDR-1 phase 3 clinical study publication

pathfndr-1 phase 3 clinical study publication.

An in-depth analysis of the efficacy and safety results of the PATHFNDR-1 phase 3 clinical study for patients with acromegaly who switched from injected SRLs to oral PALSONIFY.

View the study

PATHFNDR-2 phase 3 clinical study publication

pathfndr-2 phase 3 clinical study publication.

An in-depth analysis of the efficacy and safety results of the PATHFNDR-2 phase 3 clinical study of PALSONIFY for patients who were biochemically uncontrolled, including treatment naïve.

View the study

Patient symptom tracker tool

patient symptom tracker tool.

A daily patient-reported outcome tool for assessing and tracking key acromegaly symptoms, developed per FDA guidance, to support symptom monitoring and disease management.

iconDownload PDF
  • SRLs=somatostatin receptor ligands.

A new tool was developed to monitor acromegaly
symptoms in clinical trials11

The Acromegaly Symptom Diary (ASD) is a novel patient-reported outcome (PRO) tool. Built in accordance with FDA guidance, the ASD offers quantifiable insight into changes in acromegaly symptoms. It was designed to assess symptom severity and capture the day-to-day symptom burden that traditional biochemical markers may overlook.

The ASD in PATHFNDR studies

The ASD was used in PALSONIFY clinical trials to evaluate symptom control over time. It was completed daily during screening and during study treatment. Patients rated each symptom on a scale from 0 (no symptom) to 10 (worst symptom).

The total ASD score is the weekly average of daily scores (the sum of a scored item over 1 week divided by the number of days on which the item was completed).

The ASD tool measured symptom severity in 7 categories:
  • Headache
  • Joint pain
  • Sweating
  • Fatigue
  • Weakness in legs
  • Swelling
  • Numbness or tingling
close